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Abstract
Mental health disorders are a leading cause of disability worldwide. Challenges such as disease heterogeneity,
incomplete characterization of the targets of existing drugs and a limited understanding of functional interactions of
complex genetic risk loci and environmental factors have compromised the identification of novel drug candidates.
There is a pressing clinical need for drugs with new mechanisms of action which address the lack of efficacy and
debilitating side effects of current medications. Here we discuss a novel strategy for neuropsychiatric drug discovery
which aims to address these limitations by identifying disease-related functional responses (‘functional cellular
endophenotypes’) in a variety of patient-derived cells, such as induced pluripotent stem cell (iPSC)-derived neurons
and organoids or peripheral blood mononuclear cells (PBMCs). Disease-specific alterations in cellular responses can
subsequently yield novel drug screening targets and drug candidates. We discuss the potential of this approach in the
context of recent advances in patient-derived cellular models, high-content single-cell screening of cellular networks
and changes in the diagnostic framework of neuropsychiatric disorders.
Perspective
Current bottleneck in neuropsychiatric drug discovery
Major neuropsychiatric disorders represent a sub-
stantial burden on worldwide health, accounting for 31%
of years lived with disability (YLD)1 and a lifetime pre-
valence of over 20% of the global population (approxi-
mately 17% for major depressive disorder, 2.4% for
bipolar disorder and 1–2% for schizophrenia and autism
depending on geographic region2–4). They are asso-
ciated with significant comorbidities including cardio-
vascular disease, suicide, substance abuse, immune
disorders, obesity and diabetes1,3. Current treatments
are effective in only 40–60% of individuals5,6, providing
symptomatic relief as opposed to a cure. Other limita-
tions include debilitating side effects, such as over-
sedation and delayed-onset of therapeutic efficacy3,6.
Despite this urgent medical need, no drugs with fun-
damentally new mechanisms of action have emerged for
over two decades6,7 and many pharmaceutical compa-
nies have abandoned their neuropsychiatric R&D
initiatives altogether7.
This is largely because there is a fundamental lack of
understanding with regards to the pathophysiology of
neuropsychiatric disorders which has compromised
the identification of novel drug targets7. The major neu-
ropsychiatric medications share mechanisms of action,
including effects on monoaminergic neurotransmission7,
with compounds that were discovered serendipitously in
the 1950s and 1960s6,7. Since then the pharmaceutical
industry has focused on the development of a vast array of
monoaminergic drug derivatives with improved efficacy,
safety or administration profiles6–8. However, because the
fundamental mechanisms of drug actions have remained
similar, specific patient subgroups and symptom spectra
(such as negative symptoms in schizophrenia) which
were refractory to first generation drugs have not been
addressed by newer generation monoaminergic drugs3,7.
Likewise, the tenuous relationship between behavioral
traits in preclinical animal models and neuropsychiatric
symptoms in humans is often validated using existing
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monoaminergic drugs6,7, further precluding any
mechanistically novel pharmacophores. Finally, the full
mechanisms of action of many of the monoaminergic
drugs and non-specific binding to off-target receptors are
yet to be characterized6,7,9.
Only recently have primary targets of existing neu-
ropsychiatric drugs, such as the dopamine 2 receptor
(DRD2) or glutamate receptor subunits (GRM3,
GRIN2A, GRIA1) in schizophrenia, been linked to
genetic risk of disease at the population level through
large-scale genome-wide association studies (GWAS;
see Glossary)10. However, polygenic risk scores explain
only a fraction of genetic disease liability, for example 7%
in schizophrenia3 relative to 64–81% heritability derived
from family and twin studies11. Moreover, putative
individual GWAS risk alleles account only for a marginal
increase in disease risk with odds ratios typically under
1.1 and differences in allele frequencies between cases
and controls often less than 2%10,12. The concept that
each neuropsychiatric patient presents with a different
combination of multiple common but weak, or in some
cases rare but penetrant, risk alleles3 has led to the use of
in silico pathway analyses to identify cellular pathways
which may represent convergent drug targets at the
population level13. However, this approach is hindered
by the fact that expression quantitative trait loci (eQTL),
protein function and pathway analysis databases are
insufficiently annotated to provide meaningful func-
tional analyses relative to the molecular and cellular
complexity of the human brain. Moreover, these
resources often implicate non-specific pathophysiologi-
cal alterations such as cell motility, glycolysis, synaptic
plasticity or differentiation13, which are too general to
represent ‘druggable’ targets. This is compounded by a
limited understanding of how complex environmental
risk factors, such as childhood social adversity, maternal
infection, urbanicity, migration status or substance
abuse, interact with genetic risk loci (gene-environment
interactions) to impact disease etiology, onset and
progression3,14,15. Thus, despite the wealth of molecular
profiling data accrued in recent years it is very hard to
translate these insights into functional target-based drug
discovery (Fig. 1).
A final limitation is that the patient profiling strategies
applied to date lack the dimensionality of a true systems
biology approach, in that they do not measure the
strength of interactions between molecular risk factors
and how they change over time to impact integrated
disease phenotypes at the cellular or physiological level.
The dynamic nature of disease processes and loss of
homeostatic coping mechanisms can only be assessed
empirically if individual patient-derived samples are sub-
jected to multiple system perturbations or functional
challenges with kinetic resolution16.
Patient-derived cellular models of neuropsychiatric
disorders
Drug target discovery in neuropsychiatric disorders has
historically focused on the pathophysiology of the central
nervous system (CNS) using post-mortem brain tissue,
neuroimaging or animal model paradigms. While these
approaches have added to our understanding of the dis-
orders, they lack the vital feature of being able to assess
dynamic cellular changes in relevant human tissue.
However, the emerging concept that neuropsychiatric
disorders are systemic disorders with corresponding
manifestations in the brain and peripheral tissues17–20
suggests that different cellular models derived from per-
ipheral cells could offer an unprecedented opportunity to
screen for functional drug targets in relevant patient-
derived tissue.
Induced pluripotent stem cells (iPSCs), created by
introducing key pluripotency genes into adult somatic
cells, have received considerable attention in recent years
as a potential source of patient-derived cellular models for
neuropsychiatric disorders, including schizophrenia,
bipolar disorder, autism spectrum condition, Timothy
syndrome, Fragile X syndrome and major depressive
disorder21,22. iPSCs have been reprogrammed into a
variety of different brain cell lineages, including cortical-
excitatory, hippocampal and inhibitory neurons, micro-
glia, oligodendrocytes and astrocytes21,22. Importantly
they have demonstrated putative disease hallmarks, such
as altered neuronal connectivity in schizophrenia or
neuronal hyperexcitability in bipolar disorder, which were
reversed by antipsychotic and mood-stabilizing medica-
tions, respectively, suggesting that they could potentially
predict clinical drug efficacy. Recent developments in this
field have concentrated on scaling-up iPSC-derived cul-
tures to form more complex multi-dimensional cell net-
works which enable spatial interactions between different
cell-types to be explored. These include co-cultures of
microglia-mediated synaptic pruning23, microfluidic hip-
pocampal synapses24, neural spheroids and brain orga-
noids. Brain organoids have furthermore displayed a
diversity of brain cell types, photosensitivity and complex
cortical-like features25,26 and have been used to study
complex developmental processes such as neuronal pro-
genitor proliferation, interneuron migration and cortical
layer formation21. The use of brain organoids is still in
early stages for neuropsychiatric disorders. For example,
one single-cell RNA sequencing study reported altered
GABAergic specification and Wnt signaling in brain
organoids derived from monozygotic twins discordant for
schizophrenia27. Another study reported downregulation
of pathways involved in synaptic biology, neurodevelop-
ment and cell adhesion, concurrent with reduced stimu-
lation and depolarization responses in brain organoids
from individuals with bipolar disorder28. Nevertheless,
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organoids have been successfully employed in a number
of other disease indications such as drug repurposing
screens against Zika virus, SARS-CoV-2 infection mod-
eling and precision medicine for cystic fibrosis and a
range of cancers29.
While these iPSC-derived models represent an unpre-
cedented opportunity to explore neuropsychiatric cellular
alterations in relevant CNS tissue with the genetic back-
ground of patients, they continue to face several limita-
tions. These include difficulties in selection of the iPSC
colonies, specificity of end fate differentiation, intra-
patient variability of iPSC clones, karyotypic instability
across passages and differential power requirements for
idiopathic versus monogenic gene variants21,22. These are
compounded in the case of organoids by differences in
intrinsic versus directed patterning and the inability to
mature to postnatal stages, potentially due to lack of
vascularization21. Together, these features have meant
that this approach remains relatively high-cost, variable,
and low-throughput.
Cells which share many of the characteristics of brain
cell lineages can also be induced directly from primary
patient tissue without the need for reprogramming,
including neuronal-like cells from fibroblasts30,
microglial-like cells from peripheral monocytes31 and
olfactory neurosphere-derived cells32. Finally, CNS cell
lines or cells from control donors can be cultured in
patient-specific body fluids, for example using patient-
derived serum or cerebrospinal fluid, to investigate the
effects of disease-associated secreted factors33.
It is also possible to use primary peripheral cells in their
native state. Peripheral blood mononuclear cells
Drugs (e.g. antipscyhotics, mood stabilizers, antidepressants)
Patients (e.g. 1-2% schizophrenia, 1-2.4% bipolar disorder,
17% major depression, 1-2% autism spectrum conditions)
Cells (e.g. iPSC-derived: neurons, astrocytes, microglia,
oligodentrocytes, spheroids, organoids, 2D/ 3D co-cultures; 
PBMCs; olfactory neurophere-derived cells; induced 
fibroblasts/monocytes; serum/CSF co-cultures)  
Proteins
● Unknown interactions with environmental risk factors (e.g. childhood social adversity, 


















































● Disease heterogeneity, diagnostic (DSM-5, ICD-10) uncertainty and instability.
Functional cellular endophenotypes - 
‘dynamic responses to funtional perturbations’. 
● Unknown targets of existing drugs?
● Refractory symptom subtypes (e.g negative and cognitive symptoms of schizophrenia).
● Narrow scope of monoaminergic mechanisms of action.
● Low predictive efficacy of animal models for drugs with new 
(non-monoaminergic) mechanisms of action.
● Increased drug development risk (cost, time, regulatory restrictions, 
clinical trial failure) for CNS candidates.
High-content 
screening  
● Patient-specific combinations of multiple
common but weak, or rare but penetrant, risk alleles.
● Difficulties identifying causative genetic variants in regions of linkage-disequilibrium.
● Unknown physiological functions and interactions between proteins?
● Non-specific pathophysiological implications of pathway analyses.
● Treatment non-response (e.g. 40-60%).
● Delayed onset of therapeutic efficay (e.g. weeks-months).
● Side-effects (e.g. over-sedation, weight gain, metabolic syndrome, cardiovascular 
abnormalities, extrapyramidal symptoms, kidney toxicity).
Fig. 1 Translation gap in neuropsychiatric drug discovery. The figure summarizes the major obstacles and pending questions in neuropsychiatric
drug discovery (boxes right) at the drug, patient, environmental risk factor, protein and gene levels. Disease heterogeneity, diagnostic uncertainty and
incomplete characterization of the molecular targets of current neuropsychiatric medications have led to many patients who either do not respond
to treatment, present with treatment-refractory symptom domains or suffer from debilitating side effects. On the other hand, the genomic
complexity of neuropsychiatric disorders, in terms of multiple common but weak or rare but penetrant risk alleles (shows schematic distribution of
allele frequencies vs. odds ratios for GWAS risk loci and copy number variants adapted from ref. 3), unknown susceptibility loci (missing heritability)
and uncharacterized interactions between genetic and environmental risk factors, in addition to incomplete functional annotation of protein
interaction databases, has made it difficult to accurately prioritize potential drug targets at the cellular level based on molecular profiling data.
Functional testing of patient and control cells using ligand libraries and high-content screening provides a means to summarize the integrated
effects of multiple molecular and environmental risk factors (red) as convergent abnormalities in cellular response (‘functional endophenotypes’)
which may represent more physiologically relevant drug targets for specific patient subgroups.
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(PBMCs) are possibly the best example of this application.
They are both accessible for sampling and amenable to
high-content screening in suspension34. Consequently,
they represent a scalable model with the potential to
satisfy the power requirements of neuropsychiatric dis-
ease investigations whilst facilitating the depth of cellular
exploration necessary to reveal complex disease processes
in their native state. The majority of investigations using
PBMCs in neuropsychiatry have focused on determining
the relative proportions of different cell subsets, their
activation status or their cytokine secretion profiles35,36,
consistent with hypotheses of immunological dysfunction
in these disorders, and more recently on interactions with
the human microbiome19. However, recent data suggests
that PBMCs can also provide a surrogate model for
exploring systemic alterations in a subset of CNS drug
targets. Subtypes of CNS receptors (e.g., dopamine and
5HT receptor subtypes) and their cell signaling substrates
(e.g., Akt1 and GSK-3β) have been shown to be altered in
the brain, as well as PBMC subsets of neuropsychiatric
patients and correlated with therapeutic efficacy or dis-
ease severity17,37–39. GWAS data also suggests the
enrichment of single nucleotide polymorphisms asso-
ciated with neuropsychiatric (schizophrenia) risk loci
within PBMC subtype-specific gene expression enhan-
cers10. Moreover, PBMCs have shown preliminary evi-
dence of parallel epigenetic changes to those observed in
the brain following exposure to environmental stressors,
such as early life social adversity15,40, raising the possibi-
lity of exploring drug-target interactions which are spe-
cific to environmental risk factors. Although many of the
pathways which are shared between PBMCs and CNS
cells are likely to respond differently and the degree of
functional overlap between lineages remains to be fully
determined, recent evidence suggests that subsets of
pathways (e.g., calcium signaling via PLC-γ) or even
individual protein-protein interactions, which do overlap,
might serve as a proxy for clinically relevant targets which
are otherwise inaccessible in primary patient samples41.
Likewise, it is possible that, at least in a subpopulation of
patients, targeting proteins which mitigate immune dys-
function may contribute to symptom remission, as
exemplified by the modest efficacy of celecoxib in clinical
trials involving first-episode schizophrenia patients with
predominantly positive symptoms42.
The functional cellular endophenotype strategy for
neuropsychiatric drug discovery
The functional cellular endophenotype (see Text box)
strategy aims to directly identify abnormal functional
responses in patient-derived live cells, relative to healthy
individuals, and subsequently use these responses as novel
drug screening targets (Fig. 2)41. First, live cells (e.g., iPSC-
derived neurons, PBMCs; Fig. 2a) from patients and
controls are incubated with mechanistically diverse ligand
libraries (e.g., CNS receptor agonists, cytokines, hor-
mones, growth factors, antigens or intracellular signaling
modulators; Fig. 2b). Second, responses for each ligand
treatment relative to the vehicle are assessed across
multiple functional readouts (e.g., phosphorylation of cell
signaling proteins or mRNA expression) in parallel using
single-cell high-content screening (e.g., flow cytometry,
mass cytometry, high-content microscopy or single-cell
RNA sequencing; Fig. 2c). Third, immunophenotyping is
used to resolve responses across different cell sub-
populations (e.g., PBMC subsets or iPSC-derived cell
subtypes; Fig. 2d) within the heterogeneous cell sample.
This creates a combinatorial expansion of the number of
functional assays performed in each cell sample (Fig. 2e).
Each ligand-readout-cell subtype combination represents
a cellular response ‘node’. All nodes together provide a
profile of the functional repertoire of the cells from each
donor. In addition, the same matrix can be applied at
different time points or with different ligand doses to
provide kinetic resolution or functional titration of the
cellular responses.
Comparison of these node profiles between donors in
different clinical groups (Fig. 2f), for example neu-
ropsychiatric patients vs. healthy controls, allows the
identification of cellular responses which are altered in the
disease state. Crucially, the disease-associated cellular
responses can then be targeted through phenotypic drug
library screening to derive novel drug candidates capable
of normalizing these responses (Fig. 2g). Finally, clinically
relevant disease mechanisms linked to drug responses can
be elucidated by follow-up genomic or proteomic
experiments (Fig. 2h).
The application of this strategy is particularly relevant
for tackling complex disorders, such as neuropsychiatric
conditions. The use of patient-derived cells provides a
unique opportunity to model the genomic and epige-
nomic complexity of neuropsychiatric disorders in a
physiologically relevant context. Recent data suggests that
the genetic architecture of neuropsychiatric disorders
consists of multiple common but weak or rare but
penetrant genetic risk factors, some of which are inherited
while others may be sporadic (or ‘de novo’)3,10,43. More-
over, each patient likely has a different combination of
these risk factors. It is therefore plausible that drug targets
are best represented at the pathway level where integrated
effects of these diverse risk factors are likely to converge44.
These distinct downstream abnormalities in pathway
responses (functional endophenotypes), which are shared
by subgroups of patients despite divergent genetic back-
grounds, represent an opportunity to summarize genetic
heterogeneity, in addition to environmental risk factors, at
a time when functional interactions between risk variants
are currently too complicated to model or even unknown.
Lago et al. Translational Psychiatry          (2021) 11:128 Page 4 of 11
Examples of functional endophenotypes include altered
calcium responses in T cells at PLC−γ1 linked to ATP2A2
polymorphisms in schizophrenia41 or spontaneous cal-
cium hyperexcitability in dentate gyrus-like neurons
derived from iPSCs in bipolar disorder45. Moreover, the
use of functional testing in live cells allows the elucidation
of relevant disease-specific alterations in cellular networks
(or pathways) which are not reflected by quantitative
changes in mRNA or protein levels in their basal state, as
demonstrated by glycolytic pathway alterations following
antigenic stimulation in schizophrenia patient PBMCs46.
This includes perturbations in homeostatic and regulatory
mechanisms consistent with the concept of altered
‘cellular coping’47.
High-content single-cell functional screening
High-content screening technologies, such as flow cyto-
metry48, mass cytometry34, high-throughput microscopy49,
and single-cell RNA sequencing50, enable the depth of
functional exploration necessary to identify endopheno-
types in neuropsychiatric patient-derived cells41. The
simultaneous detection of multiple readouts (e.g., signaling
protein phosphorylation34 or mRNA expression50) in indi-
vidual cells following diverse ligand stimulation allows the
e.g. ligand library 
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Fig. 2 Neuropsychiatric drug discovery pipeline based on functional cellular endophenotypes. a Human patient-derived cells (e.g., iPSC-
derived neurons, PBMCs, olfactory neurosphere-derived cells and induced fibroblasts/monocytes) provide an accessible ex vivo model of
physiologically relevant single-cell phenotypes in health and disease. b Patient-derived cells are stimulated using ligand libraries (e.g., 01–15) and
vehicle. c Single-cell responses to the ligands are measured relative to the vehicle condition across an array of cellular readouts (e.g., phosphorylation
of cell signaling epitopes or mRNA expression; A–O) and (d) multiple cell subtypes (e.g., neuronal or PBMC subtypes; red, blue and green) using high-
content screening (e.g., flow cytometry, mass cytometry, high-throughput microscopy, multiplexed ion beam imaging and single-cell RNA
sequencing). e This produces a combinatorial expansion of the number of functional assays (e.g., 80 ligands × 80 cellular readouts × 3 cell subtypes=
19,200 assays) performed in each patient-derived cell sample with each ligand-readout-cell subtype combination defined as a cellular response
‘node’. All nodes together provide a profile of the functional repertoire of the cells from each donor. f Comparison of the node profiles between
donors in different clinical groups allows the identification of abnormal cellular responses (functional endophenotypes) which are altered in the
disease state (disease vs. control comparison), normalized by efficacious clinical treatment (treatment follow-up comparison) and specific to subsets
of neuropsychiatric disorders (multiple disease comparison). g These abnormal functional endophenotypes (e.g., depicted in red on pathway A-G)
can be targeted through phenotypic drug screening (red arrow) of compound libraries to identify novel drug candidates capable of restoring normal
cellular network function. h Further mechanistic dissection of genes and proteins underlying the functional interaction between disease
endophenotypes and drug mechanisms of action can be conducted using siRNA, CRISPR-Cas9 and small-molecule inhibitor counter-screens,
fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing. SCZ schizophrenia, BD bipolar disorder, MDD major depressive disorder,
ASC autism spectrum condition, FDA US Food and Drug Administration, NCATS National Center for Advancing Translational Sciences, CRISPR
clustered regularly interspaced short palindromic repeats gene editing.
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readouts to be correlated across thousands of single-cell
measurements in each sample. This can serve to generate
hypotheses as to causative signaling relationships and
alterations in network connectivity associated with disease
at the target discovery stage, for example increased negative
regulation within the Akt1 pathway in CD4+ T cells from
autism spectrum condition and schizophrenia patients51.
Moreover, changes in the phosphorylation activation status
of key therapeutic targets can be normalized relative to total
protein abundance or mRNA expression, a feature that has
recently revealed novel mechanisms of action for the mood
stabilizer lithium in iPSC-derived neurons from patients
with bipolar disorder52. The ability to measure multiple
markers at the single-cell level also affords the statistical
power necessary to identify clinically relevant functional
phenotypes in minority cell sub-populations within a het-
erogeneous patient-derived cell sample and define func-
tional overlap between cells from divergent lineages
(e.g., PBMCs and neurons). In this respect, computational
approaches (e.g., SPADE53, viSNE54, or CITRUS55) which
provide high-dimensional representations of deep lineage
phenotyping combined with multiple functional measure-
ments represent a valuable means for extracting disease-
associated cellular phenotypes from high-content data
without relying on prior knowledge. This has been applied
to identify cellular phenotypes relevant to prognosis in
other disease indications including acute myeloid leukemia
(AML)56. Such an approach has particular potential,
although as yet unapplied, for neuropsychiatric disorders as
it is unclear which cell subtypes represent the best func-
tional surrogates for different aspects of CNS pathology or
drug discovery indications.
An essential feature of the high-content functional
screening approach is the ability to tailor the ligands and
cellular readouts used for high-content exploration of
patient samples to increase the likelihood of relevant
drug target identification. Collectively, G-protein-coupled
receptors (GPCRs), ion channels and protein kinases and
phosphatases represent the targets for the vast majority of
currently approved medications57, especially for neu-
ropsychiatric disorders, consistent with their roles as key
cellular functional executioners. Thus, targeting these
proteins in the drug target discovery phase represents a
heuristic means for screening the most ‘druggable’ part of
the genome. Importantly, while many of these highly
functional cellular proteins, for example GPCRs, are
not easily detectable by traditional proteomic screens, an
amplified signaling event downstream of these low abun-
dance proteins can be accurately measured using fluores-
cence flow cytometry or mass cytometry34. Furthermore,
technologies such as cellular barcoding58, which permit
multiplexing of the ligand treatments, can be employed to
increase the number of functional conditions analyzed in a
limited clinical sample, for example 64 concurrent ligand
conditions applied to schizophrenia PBMCs41. Finally, at
the drug discovery stage, candidate compounds can be
screened to identify multi-target efficacies, a feature com-
mon to existing neuropsychiatric drugs, or potentially toxic
off-target interactions directly in patient samples at early
stages in the drug development pipeline. The importance of
characterizing neuropsychiatric drug interactions outside
of conventional targets is poignantly illustrated by the
association of TREK-2 potassium channel binding with
antidepressant efficacy59 or histamine H1 receptor affinity
with the side-effects of antipsychotic-induced weight gain
and sedation9. High-content resolution of cellular respon-
ses can also be used to explore synergistic interactions
between highly specific ligands acting at different sites in
the cellular network, a strategy which has shown the
potential for overcoming treatment resistance related to
genetic heterogeneity in other disease indications such as
oncology60.
Drug target prioritization and lead compound validation
One of the major challenges, having identified relevant
functional endophenotypes in neuropsychiatric patient
samples, is the prioritization of pathway responses with
potentially causal disease influences for subsequent drug
screening. In this respect, a multi-tiered approach may be
useful. First, given the possibility of multiple hits arising
from high-content screening (described below) it is
important to statistically adjust for false discoveries and
extensively cross-validate the findings using techniques
which take into account the structure of the data, such as
non-parametric permutation procedures and nested
cross-validation, as well as to consider primarily func-
tional nodes with exceptional significance in drug-naïve
patient vs. control comparisons. Second, target nodes for
which activity is correlated to disease severity at baseline
(before treatment) or to improvements in symptomatol-
ogy over the course of efficacious treatment, if long-
itudinal follow-up samples are available, are more likely to
be related to active psychopathology. Third, if genotyping
data is available for the same samples, the nodes which
correlate to polygenic risk scores, summarizing known
genetic risk, or individual risk variants might be suggestive
of targets which are supported by parallel genetic evi-
dence, at least in subgroups of patients, and could offer
mechanistic insights underlying the endophenotype.
Fourth, expression of the target node in brain tissue and/
or recapitulation of the target response in brain cell
lineages, although not essential, can serve to prioritize
targets with CNS activity. This can be further supported
by evidence of behavioral abnormalities in animal models,
in which the target node has been knocked-out or
knocked-in, or developmental changes in transgenic
model organisms such as zebrafish61. While correlation
does not necessarily imply causation, these criteria can
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serve to prioritize nodes which are more likely to repre-
sent causative variants and thus, potentially relevant
therapeutic targets. As a final consideration, nodes of
comparable significance across these criteria may be
chosen based on their amenability to high-throughput
drug screening. For example, this may include nodes with
a higher signal to noise ratio (Z-prime test), expression in
cell-types which are more easily scaled-up in a cost-
effective manner and more specific readouts (e.g., protein-
epitope phosphorylation) relative to generalized responses
(e.g., inflammatory cell proliferation).
A recent study using this approach for drug target dis-
covery in schizophrenia, assessed 3696 cell signaling
responses in PBMCs from individuals with schizophrenia
and matched controls with a six-week longitudinal follow
up41. This study prioritized an abnormal response to
thapsigargin at PLC-γ1 as the most relevant drug target
based on being the most significant node in the drug-
naïve patient vs. control comparison, normalization over
the course of efficacious clinical antipsychotic therapy,
correlation to schizophrenia risk allele loading at the
sarcoplasmic/endoplasmic reticulum calcium ATPase 2
(ATP2A2) risk locus10,62, concurrent activity in neuronal
SH-SY5Y cells and parallel evidence of schizophrenia-like
behavioral changes in animal models following forebrain-
specific ablation of PLC-γ163.
Having prioritized the relevant drug targets from
patient-derived cellular models, phenotypic drug screen-
ing can be used to identify compounds which normalize
these pathway responses and could serve as potential
novel drug candidates. This provides a means to identify
novel drug candidates even before the full spectrum and
functional interactions of putative risk alleles and envir-
onmental stressors are defined. For example, one study
focused on Timothy syndrome64, a disorder caused by a
missense mutation in L-type CaV 1.2 calcium channels
and associated with developmental delay and autism
spectrum condition, showed abnormalities in action
potential firing and calcium signaling using patch clamp
recording and calcium imaging in iPSC-derived neurons
from patients relative to controls. This was further char-
acterized to show differences in calcium-dependent gene
expression following depolarization, including tyrosine
hydroxylase, with concurrent increases in dopamine and
noradrenaline secretion. The authors then screened dif-
ferent L-type calcium channel blockers to show that the
tyrosine hydroxylase endophenotype could be improved
using roscovitine, a cyclin-dependent kinase inhibitor and
atypical L-type channel blocker. Interestingly, in the
aforementioned study relating to functional endopheno-
types in schizophrenia PBMCs, screening of an FDA-
approved compound library (n= 786) identified different
subsets of L-type calcium channel blockers (e.g., nicardi-
pine, nisoldipine and nimodipine) capable of reversing
calcium signaling deficits in response to thapsigargin at
PLC-γ141. This highlights this compound class as poten-
tially worthy of follow up across different neuropsychia-
tric indications, a feature supported by the genetic
association of L-type calcium channel subunits (e.g.,
CACNA1C and CACNB2) across several major neu-
ropsychiatric disorders65.
While this strategy represents a means to rapidly gen-
erate early stage candidates, several subsequent steps are
relevant when translating these findings towards potential
clinical trials. First, novel drug candidates can be directly
compared within the same cellular model to established
treatments, or to each other, to identify lead compounds
which show putative enhanced target specificity, cellular
potency or brain penetrance. For example, this has been
demonstrated for subtypes of 1,4-dihydropyridines within
the L-type calcium channel blocker class in phenotypic
screening of functional cellular endophenotypes in schi-
zophrenia41. Second, functional endophenotype strategies
to date have been modest in terms of sample numbers
(discussed below) and validation in larger patient cohorts
is necessary to determine whether the target response and
drug candidates are reproducible and whether there might
be heterogeneity in terms of drug response in the target
population. Third, given the overlap in genetic risk factors
between different neuropsychiatric disorders, it is
important to determine target specificity by comparing
target activity in different neuropsychiatric disorders.
Previous studies have shown that subsets of abnormalities
in cell signaling responses can be shared between different
neuropsychiatric disorders while others are unique51.
Furthermore, this heterogeneity manifests at the indivi-
dual level whereby individuals with different diagnoses
can have partially overlapping signaling profiles. Given the
changing diagnostic landscape of neuropsychiatric dis-
orders, it is plausible that targets related to symptom
subtypes which extend across diagnostic boundaries could
find utility in multiple indications. For example, one study
reported that alterations in phosphorylation responses at
proinflammatory proteins NF-κB p65 (pS529) and Stat3
(pS727) were shared between conditions with negative
symptomatology (schizophrenia and major depression)
while aberrant responses to phosphatase inhibitor caly-
culin A at S6 (pS235/pS236) were shared between con-
ditions with potential psychotic symptomatology
(schizophrenia and bipolar disorder)51. Conversely, dis-
orders which do not share the same targets can represent
relevant exclusion criteria for future clinical trials. Fourth,
novel compounds still need to undergo preclinical trials to
determine efficacy, toxicity and pharmacokinetics. Despite
the limitations of current preclinical models in terms of
equating behavioral changes to complex psychiatric
symptoms and the reliance on existing treatments as gold
standards, functional endophenotypes at least offer the
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alternative to genetically engineer the target response
instead of using acute pharmacological interventions to
precipitate symptom-like behaviors. An alternative to the
reliance on animal models is the screening of approved
medications (drug repurposing) whereby the well docu-
mented toxicology, pharmacokinetic, dosing and medic-
inal chemistry profiles of these compounds could serve to
expedite their clinical application to neuropsychiatric
indications at a lower cost relative to new chemical enti-
ties66,67. Finally, in terms of clinical trial design, the same
functional endophenotypes used for drug discovery have
the potential to serve as ex vivo treatment response pre-
dictors, which could stratify patients during clinical drug
development to overcome the heterogeneous results of
previous clinical trials. Examples include ex-vivo calcium
responses at PLC-γ1 in T cells41, glucocorticoid sensitivity
in whole blood68, or CRMP2 phosphorylation in iPSC-
derived neurons52 correlated with in vivo clinical efficacy
in schizophrenia, major depression and bipolar disorder,
respectively. In this regard, an increase in the proportion
of clinical trials which focus on drug-naïve or recent-
onset patients relative to chronic treatment-resistant
patients would help to improve the development of
effective early intervention strategies. Moreover, where
the functional target is sensitive to clinically approved
drugs ex vivo, response prediction can be used to validate
the target and support the potential in vivo efficacy of
novel drugs41.
Limitations and perspective
The functional cellular endophenotype strategy in
patient-derived cellular models represents a reverse
engineering approach. Traditional target-based, or
‘rational’, drug discovery aims to quantify pathologically-
linked gene products and propose a mechanistic drug
target using in silico pathway analysis, followed by
screening for new drugs in a purpose-built reporter sys-
tem (e.g., transfected cell line) and inferring clinical
relevance. In contrast, the functional endophenotype
strategy, proposed here, aims to identify compounds with
differential activity directly in physiologically relevant
patient-derived cells, relative to healthy individuals, and
subsequently dissect their mechanisms of action and
underlying genetic targets. Despite the progress made,
there are several limitations and key features worth con-
sidering to optimize its future utility.
First, obtaining large sample numbers of clinically well-
characterized neuropsychiatric patients and sufficient
volumes of viable patient-derived cells is a major challenge
logistically and in terms of cost. Functional endophenotype
studies to date have used relatively few samples, generally
less than ten samples for iPSC-based studies45,69,70 and up
to several dozen samples using PBMCs41,51,68, suggesting
that they are likely underpowered relative to the complexity
of neuropsychiatric phenotypes. The power requirements
for target definition using this approach therefore remain
to be accurately determined. However, the fact that rela-
tively small endophenotype strategies in schizophrenia
PBMCs (n= 12 patients for discovery, n= 30 patients for
validation)41 have identified similar lead compounds
(L-type calcium channel blockers) as suggested by much
larger GWAS studies (n= 36,989 patients)10,66 raises the
possibility that they might have lower power requirements
as a result of summarizing genetic risk at the pathway level,
a feature echoed by studies using patient iPSCs and cere-
bral organoids28,69. Nevertheless, the increased cost of
functional studies on live cells and the possibility of
expectancy bias, means that it is important to cross-
reference cellular responses with large-scale genetic and
proteomic studies such that emerging functional targets
might be interpreted in light of better-powered existing
studies as the field develops. The effect of cost in limiting
sample size is particularly relevant for iPSC-based and
organoid studies, where extended culture protocols are
needed to reprogram and differentiate cells towards neu-
ronal lineages. In these studies the trade-off between
increasing the total number of donors and increasing the
number of independent iPSC clones per donor is critical to
determining statistical power69. Although independent
iPSC clones from the same donor are vital to quantifying
intra-patient variability (derived from the transformation
and differentiation processes), it has been suggested that
the use of single iPSC lines for each donor, while max-
imizing the number of donors, may be the most efficient
strategy to maximize statistical power in light of false dis-
covery constraints69. Moreover, it is recognized that
decreasing inter-patient heterogeneity by focusing on more
genetically homogenous patient and control groups might
further improve statistical power. This can take the form of
selecting patients with highly-penetrant rare genetic var-
iants with a large effect size, patients with high polygenic
risk scores based on common variants or gene-editing (e.g.,
CRISPR-Cas9) to introduce specific risk alleles in isogenic
iPSC lines69,71. A final consideration in terms of cost is that
while cellular assays may initially be more expensive than
genotyping or steady-state protein profiling, the resulting
functional endophenotypes are more directly amenable to
drug screening. In contrast, the interpretation and engi-
neering of genomic or proteomic targets into cellular sys-
tems can represent a considerable additional cost beyond
the initial target identification.
While sample numbers remain low for patient-derived
cellular models in neuropsychiatry, initiatives like the
NextGen Genetic Association Studies Consortium, which
integrated data from over 2000 iPSC lines with GWAS
and QTL data to identify functional cellular phenotypes
for cardiovascular disease72, suggest that the same
upscaling may be possible in the field of mental health.
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In this respect, composite workflows starting with more
accessible cell types (e.g., PBMCs) followed by more
resource-intensive cellular systems (e.g., brain organoids),
or vice versa, may prove efficient and cost effective. This
will likely be complemented by recent efforts to scale-up
iPSC-derived cell types for high-throughput compound-
screening22, inclusion of a greater number of iPSCs from
complex idiopathic vs. monogenic disorders and direct
comparisons of target overlap between different cellular
models from the same individuals. Greater numbers of
valuable drug-naïve samples might also be facilitated by
including high-risk individuals (e.g., with family history of
neuropsychiatric disease) or patient groups where the
disease often remains undiagnosed (e.g., major depressive
disorder in the context of chronic stress). In line with
increasing the power of functional endophenotype stra-
tegies, it will also be crucial to leverage available data to
control for false discoveries and expectancy bias using
statistical methods such as non-parametric permutation
procedures and nested cross-validation, which take into
account the data structure.
Second, comparing cohorts with high and low polygenic
risk profile scores, or with and without rare penetrant risk
variants, across key environmental risk factors is an
essential step in understanding disease heterogeneity and
targeting treatments to specific disease aetiologies. Third,
as the diagnostic framework of neuropsychiatric disorders
evolves beyond DSM-5 and ICD-10, it will be important
to incorporate cellular responses, in addition to other
biomarker strategies, to help predict response to clinical
treatment on an individual basis and define diagnostic
categories which align more closely with therapeutic
indications. Fourth, while cellular responses to existing
neuropsychiatric treatments can be helpful to validate
functional endophenotypes, establish relevant drug dis-
covery workflows and provide clinical correlates for pre-
dicted efficacy, the field must eventually depart from the
reliance on existing medications in order to identify
mechanistically novel drugs which target resistant symp-
tom spectra and avoid the ‘catch-22 scenario’ which has
limited the scope of animal models to date.
Finally, disease mechanisms underlying functional cel-
lular endophenotypes require further dissection. Com-
plementary screening technologies such as siRNA,
CRISPR-Cas9 genome editing, or protein-specific inhibi-
tors provide opportunities to systematically knock-out or
knock-in the function of network proteins to gauge their
influence on the target response, as demonstrated in
DISC1 iPSC-neuronal models of schizophrenia73 or GSK-
3β animal models of bipolar disorder74. Fluorescence-
activated cell sorting of cells from the same patient and
cell subtype which differentially exhibit the putative
pathological response can also enable characterization of
genomic or proteomic readouts whilst controlling for
molecular variation between sample donors and cell
lineages. Lastly, the combination of technologies such a
single-cell RNA sequencing with multiplexed ion beam
imaging75 in patient-derived brain organoids could pro-
vide spatial resolution for understanding the functional
interactions between cells which drive neuropsychiatric
disease in a physiologically relevant context.
Conclusion
In conclusion, the presented approach is not the sole
solution for addressing the paucity of novel therapeutic
options for neuropsychiatric disorders. Its wider applic-
ability, including the pharmacokinetic, brain penetrance
and safety profiles of the candidate compounds, remains to
be determined in addition to better understanding which
neuropsychiatric conditions are likely to best be served by
this approach. However, in a field where primary disease
tissue is scarcely accessible and genetic complexity is
daunting, relative to the magnitude of the public health
burden, this approach could offer a complementary strat-
egy to expedite the identification of relevant drug candi-
dates and personalized treatment response predictors.
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Glossary
Cellular coping The ability of a cell to regulate the effects of a cellular
insult or stressor using homeostatic mechanisms.
Drug repurposing The identification of novel therapeutic indications for
drugs which are already approved by regulatory
agencies for the treatment of other diseases/disorders.
Functional cellular
endophenotype
Abnormal cellular response to a functional ligand in a
specific cell subtype, which is shared by subgroups of
patients relative to controls, and serves to summarize
the effect of complex genetic or environmental risk.
Gene-environment
interaction
A different effect of a genotype on disease risk in




Study which examines the association between a set of
genetic variants, distributed across the genome (usually
single-nucleotide polymorphisms), and the manifesta-
tion of different behavioral or biological traits across
individuals in a population.
High-content
screening
Method used in biological research and drug discovery
to identify substances such as small molecules, peptides
or RNAi that alter the phenotype of a cell across multiple
parameters.
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Induced pluripotent
stem cells (iPSCs)
Type of pluripotent stem cell that can be generated by




Type of circulating blood cell with a round nucleus,
including lymphocytes (T cells, B cells, NK cells) and
monocytes.
Received: 6 February 2020 Revised: 3 January 2021 Accepted: 11 January
2021
References
1. Hyman, S. E. A glimmer of light for neuropsychiatric disorders. Nature 455,
890–893 (2008).
2. Kessler, R. C., Chiu, W. T., Demler, O. & Walters, E. E. Prevalence, severity, and
comorbidity of 12-month DSM-IV disorders in the National Comorbidity
Survey Replication. Arch. Gen. Psychiatry 62, 617–627 (2005).
3. Kahn, R. S. et al. Schizophrenia. Nat. Rev. Dis. Prim. 15067. https://doi.org/
10.1038/nrdp.2015.67. (2015).
4. Akiskal, H. S. et al. Re-evaluating the prevalence of and diagnostic composition
within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 59,
S5–S30 (2000).
5. Huhn, M. et al. Efficacy of pharmacotherapy and psychotherapy for adult
psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry
71, 706–715 (2014).
6. Berton, O. & Nestler, E. J. New approaches to antidepressant drug discovery:
beyond monoamines. Nat. Rev. Neurosci. 7, 137–151 (2006).
7. Agid, Y. et al. How can drug discovery for psychiatric disorders be improved?
Nat. Rev. Drug Discov. 6, 189–201 (2007).
8. Psychiatric drug discovery on the couch. Nat. Rev. Drug Discov. 6, 171. https://
pubmed.ncbi.nlm.nih.gov/17396285/. (2007).
9. Kroeze, W. K. et al. H1-histamine receptor affinity predicts short-term weight
gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology
28, 519–526 (2003).
10. Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic
loci. Nature 511, 421–427 (2014).
11. Lichtenstein, P. et al. Common genetic determinants of schizophrenia and
bipolar disorder in Swedish families: a population-based study. Lancet 373,
234–239 (2009).
12. Disorder, B., Group, W. & America, N. Genome-wide association study identifies
30 loci associated with bipolar disorder. Nat. Genet. https://doi.org/10.1038/
s41588-019-0397-8.
13. Chang, S., Fang, K., Zhang, K. & Wang, J. Network-based analysis of schizo-
phrenia genome-wide association data to detect the joint functional asso-
ciation signals. PLoS ONE 10, 1–16 (2015).
14. Nimgaonkar, V. L., Prasad, K. M., Chowdari, K. V., Severance, E. G. & Yolken,
R. H. The complement system: a gateway to gene–environment inter-
actions in schizophrenia pathogenesis. Mol. Psychiatry 22, 1554–1561
(2017).
15. Turecki, G. & Meaney, M. J. Effects of the social environment and stress on
glucocorticoid receptor gene methylation: a systematic review. Biol. Psychiatry
79, 87–96 (2015).
16. Lehár, J. et al. Chemical combination effects predict connectivity in biological
systems. Mol. Syst. Biol. 3, 80 (2007).
17. Emamian, E. S., Hall, D., Birnbaum, M. J., Karayiorgou, M. & Gogos, J. a. Con-
vergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat.
Genet. 36, 131–137 (2004).
18. Fillman, S. G. et al. Elevated peripheral cytokines characterize a subgroup of
people with schizophrenia displaying poor verbal fluency and reduced
Broca’s area volume. Mol. Psychiatry. https://doi.org/10.1038/mp.2015.90.
(2015).
19. Rogers, G. B. et al. From gut dysbiosis to altered brain function and mental
illness: mechanisms and pathways. Mol. Psychiatry 21, 738–748 (2016).
20. Gladkevich, A., Kauffman, H. F. & Korf, J. Lymphocytes as a neural probe:
potential for studying psychiatric disorders. Prog. Neuro-Psychopharmacol. Biol.
Psychiatry 28, 559–576 (2004).
21. Wang, M., Zhang, L. & Gage, F. H. Modeling neuropsychiatric disorders using
human induced pluripotent stem cells. Protein Cell https://doi.org/10.1007/
s13238-019-0638-8 (2019).
22. Silva, M.C. & Haggarty, S.J. Human pluripotent stem cell–derived models and
drug screening in CNS precision medicine. Ann. N.Y. Acad. Sci. 1–39. https://
doi.org/10.1111/nyas.14012. (2019).
23. Sellgren, C. M. et al. Increased synapse elimination by microglia in schizo-
phrenia patient-derived models of synaptic pruning. Nat. Neurosci. 22,
374–385 (2019).
24. Sarkar, A. et al. Efficient generation of CA3 neurons from human pluripotent
stem cells enables modeling of hippocampal connectivity in vitro. Cell Stem
Cell 22, 684–697.e9 (2018).
25. Quadrato, G. et al. Cell diversity and network dynamics in photosensitive
human brain organoids. Nature 545, 48–53 (2017).
26. Velasco, S. et al. Individual brain organoids reproducibly form cell diversity of
the human cerebral cortex. Nature 570, 523–527 (2019).
27. Sawada, T. et al. Developmental excitation-inhibition imbalance underlying
psychoses revealed by single-cell analyses of discordant twins-derived cer-
ebral organoids. Mol. Psychiatry. https://doi.org/10.1038/s41380-020-0844-z.
(2020).
28. Kathuria, A. et al. Transcriptome analysis and functional characterization of
cerebral organoids in bipolar disorder. Genome Med. 12, 1–16 (2020).
29. Kim, J., Koo, B. K. & Knoblich, J. A. Human organoids: model systems for human
biology and medicine. Nat. Rev. Mol. Cell Biol. 1–14. https://doi.org/10.1038/
s41580-020-0259-3. (2020).
30. Wernig, M. et al. Neurons derived from reprogrammed fibroblasts functionally
integrate into the fetal brain and improve symptoms of rats with Parkinson’s
disease. Proc. Natl Acad. Sci. USA 105, 5856–5861 (2008).
31. Etemad, S., Zamin, R. M., Ruitenberg, M. J. & Filgueira, L. A novel in vitro human
microglia model: characterization of human monocyte-derived microglia. J.
Neurosci. Methods 209, 79–89 (2012).
32. Tee, J. Y., Sutharsan, R., Fan, Y. & Mackay-Sim, A. Schizophrenia patient-derived
olfactory neurosphere-derived cells do not respond to extracellular reelin. npj
Schizophr. 2, 16027 (2016).
33. van Rees, G. F. et al. Evidence of microglial activation following exposure to
serum from first-onset drug-naïve schizophrenia patients. Brain. Behav. Immun.
67, 364–373 (2018).
34. Bodenmiller, B. et al. Multiplexed mass cytometry profiling of cellular states
perturbed by small-molecule regulators. Nat. Biotechnol. 30, 858–867 (2012).
35. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A. & Kirkpatrick, B. Meta-analysis of
cytokine alterations in schizophrenia: clinical status and antipsychotic effects.
Biol. Psychiatry 70, 663–671 (2011).
36. Guo, J., Liu, C., Wang, Y., Feng, B. & Zhang, X. Role of T helper lymphokines in
the immune-inflammatory pathophysiology of schizophrenia: systematic
review and meta-analysis. Nord. J. Psychiatry 69, 364–372 (2015).
37. Brito-Melo, G. E. A. et al. Increase in dopaminergic, but not serotoninergic,
receptors in T-cells as a marker for schizophrenia severity. J. Psychiatr. Res. 46,
738–742 (2012).
38. Rivera-Baltanas, T. et al. Serotonin 2A receptor clustering in peripheral lym-
phocytes is altered in major depression and may be a biomarker of ther-
apeutic efficacy. J. Affect. Disord. 163, 47–55 (2014).
39. Li, X. et al. Lithium regulates glycogen synthase kinase-3beta in human per-
ipheral blood mononuclear cells: implication in the treatment of bipolar dis-
order. Biol. Psychiatry 61, 216–222 (2007).
40. Palma-Gudiel, H., Córdova-Palomera, A., Leza, J. C. & Fã Nanás, L. Glucocorticoid
receptor gene (NR3C1) methylation processes as mediators of early adversity
in stress-related disorders causality: a critical review. Neurosci. Biobehav. Rev. 55,
520–535 (2015).
41. Lago, S. G. et al. Drug discovery in neuropsychiatric disorders using high-
content single-cell screening of signaling network responses ex vivo. Sci. Adv.
5, eaau9093 (2019).
42. Zheng, W. et al. Adjunctive celecoxib for schizophrenia: a meta-analysis of
randomized, double-blind, placebo-controlled trials. J. Psychiatr. Res. 92,
139–146 (2017).
43. Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic
networks. Nature 506, 179–184 (2014).
44. Sullivan, P. F. Puzzling over schizophrenia: schizophrenia as a pathway disease.
Nat. Med. 18, 210–211 (2012).
45. Mertens, J. et al. Differential responses to lithium in hyperexcitable neurons
from patients with bipolar disorder. Nature 527, 95–99 (2015).
46. Herberth, M. et al. Impaired glycolytic response in peripheral blood mono-
nuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol.
Psychiatry 16, 848–859 (2011).
47. Wong, W. Focus issue: coping with cellular stress. Sci. Signal. 2, eg14 (2009).
Lago et al. Translational Psychiatry          (2021) 11:128 Page 10 of 11
48. Krutzik, P. O., Crane, J. M., Clutter, M. R. & Nolan, G. P. High-content single-cell
drug screening with phosphospecific flow cytometry. Nat. Chem. Biol. 4,
132–142 (2008).
49. Pegoraro, G. & Misteli, T. High-throughput imaging for the discovery of cellular
mechanisms of disease. Trends Genet. 33, 604–615 (2017).
50. Frei, A. et al. Highly multiplexed simultaneous detection of RNAs and proteins
in single cells. Nat. Methods 13, 269–277 (2016).
51. Lago, S. G. et al. Exploring the neuropsychiatric spectrum using high-content
functional analysis of single-cell signaling networks. Mol. Psychiatry. https://doi.
org/10.1038/s41380-018-0123-4. (2018).
52. Tobe, B. T. D. et al. Probing the lithium-response pathway in hiPSCs implicates
the phosphoregulatory set-point for a cytoskeletal modulator in bipolar
pathogenesis. https://doi.org/10.1073/pnas.1700111114. (2017).
53. Qiu, P. et al. Extracting a cellular hierarchy from high-dimensional cytometry
data with SPADE. Nat. Biotechnol. 29, 886–891 (2011).
54. Amir, E. D. et al. viSNE enables visualization of high dimensional single-cell
data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31,
545–552 (2013).
55. Bruggner, R. V., Bodenmiller, B., Dill, D. L., Tibshirani, R. J. & Nolan, G. P. Auto-
mated identification of stratifying signatures in cellular subpopulations. Proc.
Natl Acad. Sci. USA 111, E2770–E2777 (2014).
56. Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals
progenitor-like cells that correlate with prognosis. Cell 162, 184–197
(2015).
57. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev.
Drug Discov. 16, 19–34 (2016).
58. Krutzik, P.O. & Nolan, G.P. Fluorescent cell barcoding in flow cytometry allows
high-throughput drug screening and signaling profiling. Nat. Profil. 3, 361–368
(2006).
59. Dong, Y. Y. et al. Supplementary Materials for a complex with Prozac. 10–14.
https://doi.org/10.1126/science.1261512. (2015).
60. Thorne, C. A. et al. GSK-3 modulates cellular responses to a broad spectrum of
kinase inhibitors. Nat. Chem. Biol. 11, 58–63 (2015).
61. Thyme, S. B. et al. Phenotypic landscape of schizophrenia-associated genes
defines candidates and their shared functions. Cell 177, 478–491.e20
(2019).
62. Gordon-Smith, K. et al. Genotype-phenotype correlations in Darier disease: a
focus on the neuropsychiatric phenotype. Am. J. Med. Genet. e32679. https://
doi.org/10.1002/ajmg.b.32679. (2018).
63. Yang, Y. R. et al. Forebrain-specific ablation of phospholipase Cγ1 causes
manic-like behavior. Mol. Psychiatry 22, 1473–1482 (2017).
64. Paşca, S. P. et al. Using iPSC-derived neurons to uncover cellular phenotypes
associated with Timothy syndrome. Nat. Med. 17, 1657–1662 (2011).
65. Group, C. & Consortium, P. G. Identification of risk loci with shared effects on
five major psychiatric disorders: a genome-wide analysis. Lancet 381,
1371–1379 (2013).
66. Lencz, T. & Malhotra, A. K. Targeting the schizophrenia genome: a fast track
strategy from GWAS to clinic. Mol. Psychiatry 20, 820–826 (2015).
67. Lago, S. & Bahn, S. Clinical trials and therapeutic rationale for drug repurposing
in schizophrenia. ACS Chem. Neurosci. https://doi.org/10.1021/
acschemneuro.8b00205. (2018).
68. Carvalho, L. A. et al. Clomipramine in vitro reduces glucocorticoid receptor
function in healthy subjects but not in patients with major depression. Neu-
ropsychopharmacology 33, 3182–3189 (2008).
69. Hoffman, G.E., Schrode, N., Flaherty, E. & Brennand, K.J. New considerations for
hiPSC-based models of neuropsychiatric disorders. Mol. Psychiatry. https://doi.
org/10.1038/s41380-018-0029-1. (2018).
70. Brennand, K. et al. Modelling schizophrenia using human induced pluripotent
stem cells. Nature 473, 221–225 (2011).
71. Hoekstra, S.D., Stringer, S., Heine, V.M. & Posthuma, D. Genetically-informed
patient selection for iPSC studies of complex diseases may aid in reducing
cellular heterogeneity. Front. Cell. Neurosci. 11, 164 (2017).
72. Warren, C. R., Jaquish, C. E. & Cowan, C. A. The NextGen genetic association
studies consortium: a foray into in vitro population genetics. Cell Stem Cell 20,
431–433 (2017).
73. Wen, Z. et al. Synaptic dysregulation in a human iPS cell model of mental
disorders. Nature 515, 414–418 (2014).
74. Yang, S. et al. Deficiency in the inhibitory serine-phosphorylation of glycogen
synthase kinase-3 increases sensitivity to mood disturbances. Neuropsycho-
pharmacology 3, 1761–1774 (2010).
75. Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat.
Med. 20, 436–442 (2014).
Lago et al. Translational Psychiatry          (2021) 11:128 Page 11 of 11
